Evidence map›Paper›PMID 40378769›Full record

Trial reportNeuroImage. Clinical2025

Exploring the effect of multi-modal intervention against cognitive decline on atrophy and small vessel disease imaging markers in the AgeWell.de imaging study.

Frauke Beyer, Lukas Kleine, Andrea Zülke, Melanie Luppa, Toralf Mildner, Jochen Gensichen, Thomas Frese, David Czock, Birgitt Wiese, Hans-Helmut König and 6 more

Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in NeuroImage. Clinical, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Frauke BeyerBordeaux Population Health Research Center, University of Bordeaux, Inserm, UMR 1219, 146 rue Léo Saignat, 33076 Bordeaux, France; Cognitive Neurology, University Hospital Leipzig, University of Leipzig, Liebigstr. 18, 04103 Leipzig, Germany.
Lukas KleineCognitive Neurology, University Hospital Leipzig, University of Leipzig, Liebigstr. 18, 04103 Leipzig, Germany.
Andrea ZülkeInstitute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Philipp-Rosenthal-Strasse 55, 04103 Leipzig, Germany.
Melanie LuppaInstitute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Philipp-Rosenthal-Strasse 55, 04103 Leipzig, Germany.
Toralf MildnerNMR Group, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1a, 04103 Leipzig, Germany.
Jochen GensichenInstitute of General Practice and Family Medicine, University Hospital LMU Munich 80336 Munich, Germany.
Thomas FreseInstitute of General Practice and Family Medicine, Martin-Luther-University Halle-Wittenberg, 06112 Halle, Saale, Germany.
David CzockInternal Medicine IX - Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Birgitt WieseMHH Information Technology - Science & Laboratory, Hannover Medical School, 30625 Hannover, Germany.
Hans-Helmut KönigDepartment of Health Economics and Health Service Research, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany.
Hanna KaduszkiewiczInstitute of General Practice, University of Kiel 24105 Kiel, Germany.
Wolfgang HoffmannInstitute for Community Medicine, University Medicine Greifswald (UMG), 17489 Greifswald, Germany.
Jochen René ThyrianGerman Centre for Neurodegenerative Diseases (DZNE), site Rostock/Greifswald 17489 Greifswald, Germany; Institute for Community Medicine, University Medicine Greifswald (UMG), 17489 Greifswald, Germany; Faculty V: School of Life Sciences, University of Siegen 57076 Siegen, Germany.
Arno VillringerCognitive Neurology, University Hospital Leipzig, University of Leipzig, Liebigstr. 18, 04103 Leipzig, Germany; Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1a, 04103 Leipzig, Germany.
Steffi Riedel-HellerInstitute of Social Medicine, Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Philipp-Rosenthal-Strasse 55, 04103 Leipzig, Germany.
A Veronica WitteCognitive Neurology, University Hospital Leipzig, University of Leipzig, Liebigstr. 18, 04103 Leipzig, Germany; Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstr. 1a, 04103 Leipzig, Germany. Electronic address: veronica.witte@medizin.uni-leipzig.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultimodal lifestyle interventions might help to maintain healthy cognition in older age and to delay onset of dementia. Here, we studied the effects of a multi-modal lifestyle-based intervention, based on the FINGER trial, on magnetic resonance imaging (MRI) markers of hippocampal-limbic atrophy and cerebral small vessel disease in older adults at increased risk for dementia in Germany.

methodsLeipzig participants of the multicenter AgeWell.de randomized controlled trial underwent neuroimaging before and after a two year intervention at 3 Tesla MRI. We extracted hippocampal volume and entorhinal cortex thickness (ECT), free water fraction (FW), peak width of skeletonized mean diffusivity (PSMD), white matter hyperintensity volume and mean gray matter cerebral blood flow and assessed the effect of the intervention on these imaging markers using linear mixed models. We also tested the effect of the intervention on the hippocampus-dependent Mnemonic Similarity Test and fixel-based white matter microstructure.

results56 individuals (mean (sd) age: 68.8 (4.2) years, 26 females, 24/32 intervention/control group) were included at baseline and 41 returned after an average of 28 months for the second assessment. ECT and FW exhibited stronger decline in the intervention compared to the control group in preregistered models but not when adjusted for baseline differences. All other markers progressed similarly across groups, however sample size was smaller than expected. In exploratory analyses, cerebral blood flow increased more in the intervention group and this change was associated with decreases in systolic blood pressure.

conclusionsIn this group of older adults at risk for dementia, we find no conclusive evidence whether a multi-modal lifestyle intervention improves brain imaging markers of neurodegeneration and small vessel disease. Preliminary evidence suggested an association of the intervention, increased cerebral blood flow and systolic blood pressure reductions. ABBREVIATIONS: ECT, entorhinal cortex thickness; FW, free water fraction; WHO, world health organization; AD, Alzheimer's disease; VCI, vascular cognitive impairment; FINGER, Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability; MTL, medial temporal lobe; MIND, Mediterranean-DASH Intervention for Neurodegenerative Delay diet; cSVD, cerebral small vessel disease; WMH, white matter hyperintensities of presumed vascular origin; PSMD, peak width of the mean diffusivity distribution; WW-FINGERS, world wide FINGER studies; CAIDE, Cardiovascular Risk Factors, Aging, and Incidence of Dementia; GPP, general practitioner praxis; MRI, magnetic resonance imaging; MST, Mnemonic Similarity Test; TE, echo time; TR, repetition time; FA, flip angle; FOV, field of view; GRAPPA, GeneRalized Autocalibrating Partial Parallel Acquisition; CMRR, Center for Magnetic Resonance Research; BOLD, blood oxygenation level dependent; pcASL: pseudo-continuous arterial spin labeling; EPI, echo-planar imaging; FLAIR, fluid attenuated inversion recovery; CBF, cerebral blood flow; QA, quality assessment; GM, gray matter; HCV, hippocampal volume; eICV, estimated intracranial volume; DWI, diffusion-weighted imaging; MD, mean diffusivity; FA, fractional anisotropy
TBSS: tract-based spatial statistics; CSF, cerebral spinal fluid; ISI, inter-stimulus interval; LDI, lure discrimination index; REC, recognition score; CG, control group; IG, intervention group; MoCA, Montreal Cognitive Assessment; CASMIN, Comparative Analysis of Social Mobility in Industrial Nations; BMI, body mass index; SBP/DBP, systolic/diastolic blood pressure; OSF, open science framework; LMM, linear mixed model; ANOVA, analysis of covariance.

Indexed as

Cerebral Small Vessel DiseasesCognitive DysfunctionAgedAged, 80 and overAtrophyFemaleHippocampusHumansMagnetic Resonance ImagingMaleMiddle AgedWhite MatterCerebral Small Vessel DiseaseDementiaHippocampusLifestyleMagnetic Resonance ImagingMulti-component intervention

Identifiers

PMID40378769
PMCPMC12144455

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.